The Pro Medicus Limited (ASX: PME) share price has been a positive performer on Monday.
In morning trade the healthcare imaging software and services provider’s shares are up 1.5% to $29.25.
Why is the Pro Medicus share price pushing higher today?
Investors have been buying the company’s shares on Monday after it announced a major contract win with Northwestern Memorial HealthCare.
According to the release, Pro Medicus has signed a five-year, A$22 million deal with the Chicago-based healthcare company for its Visage 7 technology.
Visage 7 is an enterprise imaging platform that delivers fast, multi-dimensional images streamed via an intelligent thin-client viewer.
Todays’ deal extends the company’s footprint in the U.S. academic hospital segment, as well as regionally based community hospitals.
An important deal.
Pro Medicus’ Chief Executive Officer, Dr. Sam Hupert, believes this is one of the most important deals the company has signed.
He commented: “This certainly ranks up there as one of our most important not only because of the size of the deal, but also because of Northwestern’s standing in the medical and medical research communities. It will also provide us with a key reference site in the Chicago area.”
The good news for shareholders is that there may be more deals on the way. Dr Hupert revealed that its pipeline remains strong.
Commenting on other potential deals that are in the works, he said: “Some are looking at multiple products such as using Visage 7 Open Archive in addition to our Viewer, and there are also those who have expressed a preference for Cloud, so it is a good mix.”
Though, he has warned that it can take time for deals to be closed. In some cases, the whole process can take two years or even longer.
Another positive was that Pro Medicus has not experienced any major disruption from the pandemic.
Speaking about the pandemic, Dr Hupert said: “Up to now, we have not experienced any material deferral or delay in progressing any of these opportunities, Northwestern being a case in point. Our pipeline remains strong and, subject to there not being a second wave, we have a number of good opportunities across various sectors of the market that are continuing to progress through the sales cycle.”